ABL Diagnostics (XPAR:ABLD) PE Ratio without NRI: 43.61 (As of Jul. 06, 2026) — 16% Below Median


XPAR:ABLD ABL Diagnostics XPAR:ABLD
51 GF Score
Price €2.66
GF Value €7.71
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is ABL Diagnostics PE Ratio without NRI?

ABL Diagnostics XPAR:ABLD +0.76% 51 PE Ratio without NRI is 43.61 as of Jul. 06, 2026, which is 16% below its 10-year median of 51.61. GuruFocus rates XPAR:ABLD with a GF Score™ of 51/100 and a GF Value™ of €7.71 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 437 Healthcare Providers & Services companies, ABL Diagnostics ranks worse than 77.12% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-06), ABL Diagnostics's share price is €2.66. ABL Diagnostics's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €0.06. Therefore, ABL Diagnostics's PE Ratio without NRI for today is 43.61.

During the past 13 years, ABL Diagnostics's highest PE Ratio without NRI was 578.57. The lowest was 23.95. And the median was 51.61.

ABL Diagnostics's EPS without NRI for the six months ended in Dec. 2025 was €0.05. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €0.06.

As of today (2026-07-06), ABL Diagnostics's share price is €2.66. ABL Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.06. Therefore, ABL Diagnostics's PE Ratio (TTM) for today is 43.61.

Good Sign:

ABL Diagnostics stock PE Ratio (=43.61) is close to 3-year low of 39.34.

During the past years, ABL Diagnostics's highest PE Ratio (TTM) was 3233.33. The lowest was 1.58. And the median was 17.86.

ABL Diagnostics's EPS (Diluted) for the six months ended in Dec. 2025 was €0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.06.

ABL Diagnostics's EPS (Basic) for the six months ended in Dec. 2025 was €0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.06.


ABL Diagnostics  (XPAR:ABLD) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


ABL Diagnostics PE Ratio without NRI Related Terms


ABL Diagnostics PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for ABL Diagnostics's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ABL Diagnostics PE Ratio without NRI Chart

ABL Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss 336.09 N/A 175.71 48.39

ABL Diagnostics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A At Loss 175.71 At Loss 48.39

XPAR:ABLD vs VEEV, BTSG, TEM: PE Ratio without NRI Comparison

For the Health Information Services subindustry, ABL Diagnostics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ABL Diagnostics PE Ratio without NRI vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where ABL Diagnostics's PE Ratio without NRI falls into.


XPAR:ABLD
51GF Score
ABL Diagnostics XPAR:ABLD
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ABL Diagnostics PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

ABL Diagnostics's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=2.66/0.061
=43.61

ABL Diagnostics's Share Price of today is €2.66.
For company reported semi-annually, ABL Diagnostics's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.06.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 43.61 mean?
ABL Diagnostics (XPAR:ABLD) has a PE Ratio without NRI of 43.61 as of Jul. 06, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on ABL Diagnostics and its competitors. This is 16% below median its historical median of 51.61. Over the past decade, ABL Diagnostics' PE Ratio without NRI has ranged from 23.95 to 578.57. According to the industry distribution chart, ABL Diagnostics ranks #337 out of 437 companies in the Healthcare Providers & Services industry, placing it in the top 77.1%.
Is ABL Diagnostics' PE Ratio without NRI too high?
ABL Diagnostics' current PE Ratio without NRI of 43.61 is 16% below median its 10-year median of 51.61. Over the past 10 years, this metric has ranged from a low of 23.95 to a high of 578.57. The Healthcare Providers & Services industry median PE Ratio without NRI is 20.07. ABL Diagnostics' value of 43.61 is 117.3% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #337 out of 437 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, ABL Diagnostics has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' PE Ratio without NRI compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #337 out of 437 companies for PE Ratio without NRI. This places ABL Diagnostics in the lower half of its industry. The industry median PE Ratio without NRI is 20.07. ABL Diagnostics' value of 43.61 is 117.3% above this benchmark. Historically, ABL Diagnostics' own PE Ratio without NRI has ranged from 23.95 to 578.57 over the past decade. While the company's 10-year median is 51.61 vs. the industry median of 20.07, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Healthcare Providers & Services company?
The median PE Ratio without NRI among Healthcare Providers & Services companies is 20.07, based on 437 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current PE Ratio without NRI of 43.61 is 117.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median PE Ratio without NRI is 20.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current PE Ratio without NRI is 43.61, which is 16% below median its own 10-year median of 51.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.71, compared to a current price of €2.66 — trading 65.5% below its estimated fair value. The current PE Ratio without NRI is 43.61, which is 16% below median its 10-year median of 51.61 and 117.3% above the Healthcare Providers & Services industry median of 20.07. ABL Diagnostics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current PE Ratio without NRI is 43.61 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?

Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued. The current stock price of €2.66 is trading 65.5% below its estimated GF Value™ of €7.71. GuruFocus considers ABL Diagnostics to be Significantly Undervalued.

Key valuation signals for XPAR:ABLD:

  • PE Ratio without NRI: 43.61 (16% below median its 10-year median of 51.61)
  • GF Value™: €7.71 vs. price of €2.66 (65.5% below fair value)
  • GF Score™: 51/100 with 4 warning signs
  • Industry Position: 117.3% above the Healthcare Providers & Services median (#337 of 437)

No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ABL Diagnostics Business Description

Other Exchanges 9BK0:Germany
Address 72c, rue de, WOIPPY, Thionville, FRA, 57140
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
51GF Score

Get the complete analysis for XPAR:ABLD

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.66
Price
€7.71
GF Value